![]() |
市场调查报告书
商品编码
1776198
切片机的全球市场 - 市场考察,竞争情形,市场预测(2032年)Microtome - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
预计 2025 年至 2032 年期间,全球切片机市场将以 6.13% 的复合年增长率成长。切片机的需求主要源自于慢性疾病发生率的上升,例如癌症、传染病、心血管疾病(例如动脉粥状硬化、心肌梗塞和心肌病变)以及呼吸系统疾病(例如气喘和慢性阻塞性肺病 (COPD))。此外,全球生物医学研究和药物开发活动的不断扩展也推动了切片机的需求。研究人员对用于分子诊断、药物研发和个人化医疗的高品质组织切片的需求,将在预测期内(2025-2032 年)推动切片机市场的发展。
切片机市场动态
根据国际癌症研究机构 (2024) 提供的数据,2022 年全球新增癌症病例约 2,000 万例。该机构还报告称,在这些新增癌症病例中,肺癌最为常见,全球新增病例达 250 万例;其次是乳腺癌,新增病例达 230 万例;结直肠癌,新增病例达 190 万例;胃肠癌,新增病例达 97 万例。
全球癌症观察组织 (2024) 估计,到 2030 年,全球将新增 2,000 万至 2,410 万例癌症病例。此外,预计新增癌症病例的地区包括亚洲(9,826,539 例)、欧洲(4,471,422 例)、拉丁美洲和加勒比地区(1,551,060 例)以及非洲(1,185,216 例)。
癌症的诊断和治疗在很大程度上依赖准确的组织检查。随着癌症发生率的上升,切片机越来越普遍地用于製备高品质的组织切片以进行显微分析。癌症患者数量的快速成长推动了切片机市场的扩张。
此外,在结核病、肝炎、新冠肺炎 (COVID-19) 和真菌感染等传染病爆发期间,对活检组织进行组织病理学评估对于识别病原体、评估组织损伤程度和监测病情进展至关重要。根据世界卫生组织 (WHO) 提供的数据,预计到 2023 年,全球将有 1,080 万人感染结核病,其中包括 600 万名男性、360 万名女性和 130 万名儿童。此外,根据相同来源估计,到2022年,全球将有2.54亿人感染B肝,5,000万人感染C肝,每天新增6,000例病毒性肝炎病例。切片机对于製作薄而均匀的组织切片至关重要,这些切片可在显微镜下染色和检查以进行确诊,从而推动整个切片机市场的发展。
因此,预计所有上述因素都将在预测期内推动切片机市场的发展。
然而,冷冻切片和雷射显微切割等替代样品製备技术的出现,可能会减少对传统切片机的依赖,从而限制最终用户群,并抑制预测期内切片机市场的成长。
预计北美将主导整个切片机市场。
预计到2024年,北美将在所有地区中占据切片机市场的最大占有率。这是由于北美癌症患者和传染病患者的持续成长。此外,高端医疗基础设施和现有的高科技设备、先进癌症诊断检测和筛检的前景不断扩大、病理实验室的优惠报销政策、不断上涨的医疗成本以及该地区众多市场参与者的存在,预计将推动北美切片机市场的成长。
美国国家癌症研究所(2024)估计,到2024年底,美国将诊断出200万例新发癌症病例。此外,摄护腺癌、肺癌和大肠癌估计约占男性所有癌症诊断的48%。乳癌、肺癌和大肠癌是最常见的癌症,预计将占所有新诊断癌症的 51% 左右。
本报告研究并分析了全球切片机市场,提供了市场规模和预测、过去三年产品/技术发展、主要市场参与者以及可用机会等资讯。
Microtome Market by Product (Microtome [Rotary Microtome, Vibrating Microtome, and Others] and Accessories [Blades and Knives, Cooling Clamp, and Others]), Technology (Fully Automated, Semi-Automated, and Manual), End-User (Hospitals, Diagnostic Clinics, Academic and Research Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing cases of chronic disorders, increase in research and development activities, among others globally.
The microtome market is estimated to grow at a CAGR of 6.13% during the forecast period from 2025 to 2032. The demand for microtomes is primarily being boosted by the increasing cases of chronic disorders such as cancer, infectious disease, cardiovascular diseases, including atherosclerosis, myocardial infarction, and cardiomyopathies, respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), and others. Additionally, the expansion of biomedical research and pharmaceutical development activities worldwide is fueling the demand for microtomes. Researchers require high-quality tissue sections for molecular diagnostics, drug discovery, and personalized medicine, thus boosting the market for microtomes during the forecast period from 2025 to 2032.
Microtome Market Dynamics:
According to data provided by the International Agency for Research on Cancer (2024), in 2022, approximately 20 million new instances of cancer were registered globally. Additionally, as per the same source, lung cancer accounted for 2.5 million new cases globally, of all the registered new cancer cases, making it the most common cancer. Next in order of incidence were breast cancer with 2.3 million cases, colon cancer with 1.9 million cases, and stomach cancer with 0.97 million cases globally.
The Global Cancer Observatory (2024) estimated that the new instances of cancer globally would range from 20 million to 24.1 million by the year 2030. Moreover, it stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
Since cancer diagnosis and treatment rely heavily on accurate tissue examination, the rising cancer rates necessitate the widespread use of microtomes to prepare high-quality tissue sections for microscopic analysis. This surge in cancer cases translates into a larger market for microtomes.
Additionally, during outbreaks of infectious diseases such as tuberculosis, hepatitis, COVID-19, and fungal infections, histopathological evaluation of biopsied tissues becomes essential to identify the pathogen, assess the extent of tissue damage, and monitor disease progression. According to the data provided by the World Health Organization, in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Additionally, as per the same source, in 2022, an estimated 254 million people were living with hepatitis B and 50 million people were living with hepatitis C worldwide, and 6000 people were newly infected with viral hepatitis each day. Microtomes are crucial in preparing thin, uniform tissue sections that are stained and examined under microscopes for definitive diagnosis, thereby boosting the overall market of microtomes.
Therefore, all the above-mentioned factors are expected to drive the market for microtomes during the given forecast period.
However, the availability of alternative sample preparation technologies, such as cryo-sectioning and laser microdissection, could reduce the reliance on traditional microtomes, acting as factors that are expected to limit their end-user base, thus restricting the growth of the microtome market during the forecast period.
Microtome Market Segment Analysis:
Microtome Market by Product (Microtome [Rotary Microtome, Vibrating Microtome, and Others] and Accessories [Blades and Knives, Cooling Clamp, and Others]), Technology (Fully Automated, Semi-Automated, and Manual), End-User (Hospital, Diagnostic Clinics, Academic and Research Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the technology segment of the microtome market, the fully automated category of microtome is estimated to amass a significant revenue share in the microtome market in 2024. This can be attributed to the large patient population associated with various chronic disorders and the presence of a variety of products available to this category.
Fully automated microtomes offer several advantages and diverse applications, significantly enhancing the field of histopathology. Their primary benefits are to produce consistent high quality tissue sections with minimal user intervention, ensuring precision and reproducibility. This automation reduces the risk of human error and variability, which is crucial for accurate diagnosis.
In terms of applications, fully automated microtomes are invaluable in cancer diagnostics, where they provide fine tissue sections needed for detailed examination of tumor morphology and margins. They are also extensively used in research settings to study disease mechanisms at the cellular level, contributing to the development of new treatments and therapies. These advanced instruments are employed in various medical fields, including neuropathology, dermatopathology, and cardiovascular pathology, where precise tissue sectioning is critical for studying complex structures and diagnosing conditions.
Additionally, the presence of a huge number of commercially available fully automated systems and the increasing demand for digitalization in tissue diagnostic procedures are some of the crucial factors anticipated to boost the market in the next few years. Some of the key automated products include Microtome A550, Tissue-Tek Genie, and Leica Biosystems HistoCore AUTOCUT 2550.
Therefore, the various advantages and applications provided by fully automated microtomes will contribute to the growth of this category, thereby driving the growth of the overall microtome market during the forecast period.
North America is expected to dominate the overall microtome market:
North America is expected to account for the highest proportion of the microtome market in 2024, out of all regions. This is owing to the continual increase in cancer cases and infectious diseases in the North America region. Moreover, the high-end medical infrastructure paired with readily available high-tech equipment, expanding prospects for sophisticated cancer diagnostic testing and screening, favorable reimbursement policies for pathology labs, rise in healthcare spending, presence of a large number of market players in the region are expected to drive the growth of the microtome market in North America.
The National Cancer Institute (2024) estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, it was estimated that prostate, lung, and colorectal cancers were expected to represent approximately 48% of all cancer diagnoses in men. The most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases, and Canada represented 10.9% of all cancer cases. The reliance on microtomes for accurate tissue sectioning in cancer diagnosis and research is paramount. Microtomes are essential for producing high-quality tissue samples for identifying cancer types, understanding disease progression, and tailoring treatment plans. Consequently, the rising instances of cancer catalyze the demand for microtomes, hence propelling market growth.
According to the recently updated data provided by the Centers for Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. The high incidence of myocardial infarctions necessitates extensive histological examination of cardiac tissues to understand the underlying causes. Microtomes are essential in preparing thin, detailed sections of heart tissue for microscopic analysis, enabling pathologists to examine cellular structures, detect abnormalities, and evaluate the effectiveness of treatment, therefore boosting its market growth.
According to the American Lung Association data updated in April 2024, it stated that more than 34 million people were living in the US with chronic lung diseases like asthma and COPD. These disorders underscore the growing need for microtomes in diagnostic pathology because of their ability to produce high-quality lung tissue sections for microscopic analysis, which is vital for diagnosing, understanding, and treating these conditions, consequently boosting the market for microtomes.
Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in the North America microtome market growth during the forecast period from 2025 to 2032.
Microtome Market Key Players:
Some of the key market players operating in the microtome market include Thermo Fisher Scientific Inc., AGD Biomedicals Pvt. Ltd., SLEE medical GmbH, Diapath S.p.A., Leica Biosystems Nussloch GmbH, Green Leaf Scientific, MEDITE Medical GmbH, LLS ROWIAK LaserLabSolutions GmbH, Amos Scientific PTY. LTD, RWD Life Science Co., Sakura Finetek, Boeckeler Instruments, Inc., HACKER Instruments & Industries Inc., microTec Laborgerate GmbH, Bright Instrument Co Limited, JINHUA YIDI MEDICAL APPLIANCES CO., LTD, FEATHER Safety Razor Co., Ltd., Precisionary Instruments, Powered Milestone Srl, Weinkauf Medizintechnik, and others.
Recent Developmental Activities in the Microtome Market:
Key takeaways from the microtome market report study
Target audience who can benefit from this microtome market report study
Frequently Asked Questions for the Microtome Market: